Next Article in Journal
Briarenolides F and G, New Briarane Diterpenoids from a Briareum sp. Octocoral
Previous Article in Journal
Biochemical Studies of the Lagunamides, Potent Cytotoxic Cyclic Depsipeptides from the Marine Cyanobacterium Lyngbya majuscula
Article

Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog

1
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
2
Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL 35294, USA
3
Cancer Biology Center, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
4
Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Mar. Drugs 2012, 10(5), 1138-1155; https://0-doi-org.brum.beds.ac.uk/10.3390/md10051138
Received: 30 March 2012 / Revised: 2 May 2012 / Accepted: 16 May 2012 / Published: 23 May 2012
We have recently designed and synthesized a novel iminoquinone anticancer agent, 7-(4-fluorobenzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one (FBA-TPQ) and initiated its preclinical development. Herein we investigated its efficacy, safety, and pharmacokinetics in in vitro and in vivo models of human pancreatic cancer. Our results demonstrated that FBA-TPQ inhibited pancreatic cancer cell growth, induced apoptosis, and caused cell cycle arrest in vitro. It inhibited the growth of xenograft tumors with minimal host toxicity. To facilitate future preclinical and clinical development of the agent, we also developed and validated a Rapid Resolution Liquid Chromatography (RRLC) method for quantitative analysis of FBA-TPQ in plasma and tissue samples. The method was found to be precise, accurate, and specific. Using this method, we carried out in vitro and in vivo evaluations of the pharmacological properties of FBA-TPQ, including stability in plasma, plasma protein binding, metabolism by S9 enzymes, plasma pharmacokinetics, and tissue distribution. Our results indicate that FBA-TPQ is a potential therapeutic agent for pancreatic cancer, providing a basis for future preclinical and clinical development. View Full-Text
Keywords: pancreatic cancer; marine anticancer agents; RRLC; pharmacokinetics pancreatic cancer; marine anticancer agents; RRLC; pharmacokinetics
Show Figures

Figure 1

MDPI and ACS Style

Zhang, X.; Xu, H.; Zhang, X.; Voruganti, S.; Murugesan, S.; Nadkarni, D.H.; Velu, S.E.; Wang, M.-H.; Wang, W.; Zhang, R. Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog. Mar. Drugs 2012, 10, 1138-1155. https://0-doi-org.brum.beds.ac.uk/10.3390/md10051138

AMA Style

Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang M-H, Wang W, Zhang R. Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog. Marine Drugs. 2012; 10(5):1138-1155. https://0-doi-org.brum.beds.ac.uk/10.3390/md10051138

Chicago/Turabian Style

Zhang, Xiangrong, Hongxia Xu, Xu Zhang, Sukesh Voruganti, Srinivasan Murugesan, Dwayaja H. Nadkarni, Sadanandan E. Velu, Ming-Hai Wang, Wei Wang, and Ruiwen Zhang. 2012. "Preclinical Evaluation of Anticancer Efficacy and Pharmacological Properties of FBA-TPQ, a Novel Synthetic Makaluvamine Analog" Marine Drugs 10, no. 5: 1138-1155. https://0-doi-org.brum.beds.ac.uk/10.3390/md10051138

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop